Literature DB >> 17083361

Expression pattern of somatostatin receptor subtypes 1-5 in human skin: an immunohistochemical study of healthy subjects and patients with psoriasis or atopic dermatitis.

Lena Hagströmer1, Lennart Emtestam, Mats Stridsberg, Toomas Talme.   

Abstract

In psoriasis and atopic dermatitis, the inflammatory events have neurogenic components and the neuropeptides modify the functions of immuno-active cells in the skin. Somatostatin is a neuropeptide with several neuroendocrine and immunomodulating properties and mediates its actions by five distinct subtypes of G-protein-coupled receptors (SSTR1-5). This study describes the distribution of SSTR1-5, analysed with immunohistochemistry, in psoriasis, atopic dermatitis and controls. Normal human skin and lesional skin from patients with psoriasis or atopic dermatitis showed many similarities, but also some differences, as regards SSTR expression. SSTR1-3 were strongly expressed in the epidermis of healthy skin, and in the skin of patients with psoriasis or atopic dermatitis. It is noteworthy that SSTR4 and 5 were strongly expressed in the epidermis of psoriasis patients, but weakly expressed in the epidermis of those with atopic dermatitis and normal skin. The intensity of the staining also varied considerably between the different layers of the epidermis, especially in psoriasis patients. In all cases, the dendritic cells, found mostly in the papillary and upper reticular dermis, showed a strong expression of SSTR1-4, but a weak expression of SSTR5. SSTR1-5 were strongly expressed in the sweat glands in all skin biopsies. Hair follicles and sebaceous glands expressed all five subtypes. Striated muscle fibres showed an intense positive expression of SSTR1-4, but a weak or negative expression of SSTR5. The wide distribution and expression pattern of all five SSTRs in human skin suggest that somatostatin is involved in the interactions between the nervous system and the skin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083361     DOI: 10.1111/j.1600-0625.2006.00487.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  8 in total

1.  Hormones and the pilosebaceous unit.

Authors:  Wen-Chieh Chen; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2009-03

2.  Neuroendocrine regulators: Novel trends in sebaceous gland research with future perspectives for the treatment of acne and related disorders.

Authors:  Markus Böhm
Journal:  Dermatoendocrinol       Date:  2009-05

3.  Somatostatin inhibits cell migration and reduces cell counts of human keratinocytes and delays epidermal wound healing in an ex vivo wound model.

Authors:  Matthias Vockel; Simone Pollok; Ute Breitenbach; Ina Ridderbusch; Hans-Jürgen Kreienkamp; Johanna M Brandner
Journal:  PLoS One       Date:  2011-05-11       Impact factor: 3.240

4.  Nerve growth factor, neuropeptides and cutaneous nerves in atopic dermatitis.

Authors:  Abeer Hodeib; Zeinab Abd El-Samad; Hesham Hanafy; Amani Abd El-Latief; Amal El-Bendary; Azza Abu-Raya
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

5.  Exploiting Gene-Expression Deconvolution to Probe the Genetics of the Immune System.

Authors:  Yael Steuerman; Irit Gat-Viks
Journal:  PLoS Comput Biol       Date:  2016-04-01       Impact factor: 4.475

6.  Effects of AP‑1 and NF‑κB inhibitors on colonic endocrine cells in rats with TNBS‑induced colitis.

Authors:  Magdy El-Salhy; Kazuo Umezawa
Journal:  Mol Med Rep       Date:  2016-06-27       Impact factor: 2.952

Review 7.  Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.

Authors:  Magdy El-Salhy; Tefera Solomon; Trygve Hausken; Odd Helge Gilja; Jan Gunnar Hatlebakk
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

Review 8.  The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis.

Authors:  Lai-San Wong; Yu-Ta Yen; Chih-Hung Lee
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.